Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,909 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06654011RecruitingPhase 2
A study testing a new combination for rare cervical cancer
This trial tests whether adding the drug IN10018 to a standard chemotherapy and immunotherapy combination can help treat a rare type of cervical cancer called gastric-type adenocarcinoma that has spread or come back. The goal is to see if this combination improves outcomes for patients who have already had at least one round of chemotherapy.
Wuhan, HubeiAges 18–75 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT04938986Recruiting
Testing a tumor marker to predict colon cancer relapse risk
This study looks at whether a lab test on your tumor can better predict the chance that non-metastatic colon cancer will come back after surgery. Researchers will compare relapse risk using the Immunoscore® test to help guide follow-up and treatment decisions.
MarseilleAges 18–80 - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT07631572Recruiting
Cesium implant radiation for recurrent cervical or uterine cancer
This study tests a type of internal radiation (cesium implant) to treat cancer that has come back in the vagina after previous pelvic radiation. The goal is to save the organ while treating the cancer.
Lexington, KentuckyAges 18 years+ - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT06458413RecruitingPhase 2
Utidelone plus capecitabine for metastatic breast cancer
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Zhengzhou, HenanAges 18–70 - NCT06889649RecruitingPhase 2
SBRT plus immunotherapy and targeted therapy for kidney cancer
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT07741435Recruiting
Simple blood, urine, and saliva test to find cancer early
This study tests a new way to find cancer by looking at DNA in blood, urine, and saliva. It may help detect cancer earlier and monitor how well treatment works.
Bogotá, Bogota D.C.Ages 18 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT03617133RecruitingPhase 2
MRI-guided radiation plus chemo for cervical cancer
This trial tests a more precise way to deliver radiation for locally advanced cervical cancer using MRI guidance during treatment, along with chemotherapy. It may help shrink tumors more effectively while aiming to reduce side effects by targeting the right areas.
ViennaAges 18–99 - NCT03646955Recruiting
Partial breast radiation versus no radiation after lumpectomy
This trial compares giving radiation only to part of the breast versus not giving radiation at all after breast-conserving surgery. It’s meant for women with early, hormone-driven breast cancer to see if skipping radiation can be safe and reduce treatment burden.
SantiagoAges 60 years+ - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT05045066RecruitingEarly Phase 1
Vitamin D treatment study for Black men with prostate cancer
This early-phase study looks at how vitamin D replacement affects the immune system in Black/African American men with prostate cancer. It’s testing whether bringing vitamin D levels into a healthier range changes immune signals that may matter for cancer health.
Scottsdale, ArizonaAges 18 years+ - NCT05501353Recruiting
Study tumor biomarkers in recurrent metastatic colon cancer
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Hangzhou, ZhejiangAges 18–99 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT05932212RecruitingPhase 2
Study drug for vulvar cancer after prior treatment failure
This Phase 2 trial tests AK104 in people with recurrent or metastatic vulvar cancer that cannot be cured with surgery or strong radiation. It may help shrink tumors or slow growth, especially if you’ve already tried standard treatments or couldn’t tolerate them.
Fuzhou, FujianAges 18–80 - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06147960Recruiting
Cancer cell proteins and cervical cancer return risk
This trial looks at whether certain proteins that stop cell death (called inhibitor of apoptosis proteins) in cervical cancer tissue can help predict if the cancer will come back after treatment. It studies patients who had chemoradiation for advanced cervical cancer.
Nîmes, GardAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,909 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.